Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations.
Authors
Secq V, Villeret J, Fina F, Carmassi M, Carcopino X, Metellus I, Boubli L, Iovanna J, Charpin C
Summary
The amplification of epidermal growth factor receptor (EGFR) in triple negative breast carcinomas (TNBC) suggests its potential therapeutic application, as for HER-2, using standardised methods of measurement. In this regard, we aimed to compare several methods for evaluating EGFR amplification along with potential mutations for suitability in clinical practice.
Read the article